Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03330821 | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 53 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02091245 | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | active not recruiting | Phase 1 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06445907 | Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05157971 | Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT02632708 | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | active not recruiting | Phase 1 | 153 | Institut de Recherches Internationales ServierOTHER | 3 | May 22, 2026 | clinicaltrials |
| NCT03613532 | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | active not recruiting | Phase 1 | 102 | Jacqueline Garcia, MDOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02334865 | SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy | active not recruiting | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04067336 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 263 | Kura Oncology, Inc.INDUSTRY | 7 | May 13, 2026 | clinicaltrials |
| NCT04150887 | Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia(ELEVATE) | active not recruiting | Phase 1 | 61 | OncoVerity, Inc.INDUSTRY | 5 | May 12, 2026 | clinicaltrials |
| NCT05088356 | Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft | active not recruiting | Phase 1 | 66 | Stanford UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03770429 | AZD6738 for Patients With Progressive MDS or CMML | active not recruiting | Phase 1 | 52 | Massachusetts General HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03984968 | CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT03560882 | A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | active not recruiting | Phase 1 | 50 | Joaquina BarandaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04872790 | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | active not recruiting | Phase 1 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT02029443 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 306 | Acerta Pharma BVINDUSTRY | 3 | May 5, 2026 | clinicaltrials |
| NCT04493138 | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | active not recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05618028 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | active not recruiting | Phase 1 | 78 | AbbVieINDUSTRY | 10 | May 4, 2026 | clinicaltrials |
| NCT03913949 | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies | active not recruiting | Phase 1 | 74 | Ascentage Pharma Group Inc.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT04898894 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | active not recruiting | Phase 1 | 37 | St. Jude Children's Research HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03479268 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05396859 | Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | active not recruiting | Phase 1 | 13 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05428969 | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies(BEXMAB) | active not recruiting | Phase 1 / Phase 2 | 181 | Faron Pharmaceuticals LtdINDUSTRY | 3 | Apr 23, 2026 | clinicaltrials |
| NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | active not recruiting | Phase 1 | 150 | Nkarta, Inc.INDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT05222984 | Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | active not recruiting | Phase 1 | 17 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT00466531 | Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | active not recruiting | Phase 1 / Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03132454 | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | active not recruiting | Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03192397 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03085173 | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | active not recruiting | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03793478 | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | active not recruiting | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 10 | Apr 1, 2026 | clinicaltrials |
| NCT04980404 | Inqovi Maintenance Therapy in Myeloid Neoplasms | active not recruiting | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT00819546 | RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS | active not recruiting | Phase 1 | 29 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03534323 | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS | active not recruiting | Phase 1 / Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04629729 | FT819 in Subjects With B-cell Malignancies | active not recruiting | Phase 1 | 54 | Fate TherapeuticsINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03844815 | Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 26 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03974217 | Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts | active not recruiting | Phase 1 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06052813 | A Study of BN104 in the Treatment of Acute Leukemia | active not recruiting | Phase 1 / Phase 2 | 66 | Institut de Recherches Internationales Servier (I.R.I.S.)INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT00544466 | Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies | active not recruiting | Phase 1 / Phase 2 | 75 | City of Hope Medical CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT02158091 | A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | active not recruiting | Phase 1 / Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06325748 | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | active not recruiting | Phase 1 | 21 | Senti BiosciencesINDUSTRY | 2 | Feb 12, 2026 | clinicaltrials |
| NCT00586391 | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL(CRETI-NH) | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05016947 | Venetoclax Plus Inotuzumab for B-ALL | active not recruiting | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05455294 | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | active not recruiting | Phase 1 | 16 | Jacqueline Garcia, MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03842696 | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | active not recruiting | Phase 1 / Phase 2 | 43 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05001828 | Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia | active not recruiting | Phase 1 | 38 | Polaris GroupINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06768476 | CART123 + Ruxolitinib in Relapsed/Refractory AML(AML) | active not recruiting | Phase 1 | 12 | University of PennsylvaniaOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05942599 | Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation(CARAML) | active not recruiting | Phase 1 | 10 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04843904 | Safe Accelerated Venetoclax Escalation in CLL(SAVE) | active not recruiting | Phase 1 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03912064 | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | active not recruiting | Phase 1 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03330691 | A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia | active not recruiting | Phase 1 | 78 | Seattle Children's HospitalOTHER | 2 | Dec 15, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 1, 2026source: clinicaltrials